Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

The healthcare giant's relatively strong preliminary third-quarter results were overshadowed by two other developments.

Here's Why Baxter International Fell as Much as 12.4% Today

Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.

Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance

Baxter stock tumbled after the medtech company launched accounting probe and reported weak Q3 sales. Integra earnings topped.

Baxter Dives On Accounting Probe; Integra Earnings Top

Abbott Labs

Labcorp Holdings Inc

ResMed

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.

What's in the Offing for Baxter's (BAX) Earnings in Q3?

Hill-Rom Hlds

HRC vs. BAX: Which Stock Is the Better Value Option?

HRC or BAX: Which Is the Better Value Stock Right Now?

Boston Scientific

BAX vs. BSX: Which Stock Is the Better Value Option?

BAX or BSX: Which Is the Better Value Stock Right Now?

Medtronic

Symantec Corp

Target

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Five High-Flying Stocks Near 52-Week High - That Can Scale Higher

Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.

Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring

General Electric

Anadarko Petroleum

DXC Technology

News Corp

Bill Nygren (Trades, Portfolio), manager of the Oakmark Fund, sold shares of the following stocks in the second quarter.

Bill Nygren Trims General Electric, Baxter International and others

Baxter (BAX) reported earnings 30 days ago. What's next for the stock?

Why Is Baxter (BAX) Down 0.2% Since Last Earnings Report?

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Bristol-Myers

Cardinal Health

Healthpeak Properties Inc

Healthcare stocks are among the best growth and income plays. Here are five firms in the sector that have the goods to keep growing and paying strong dividends.

5 Healthcare Stocks to Buy for Healthy Dividends

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

Here's Why You Should Snap Up Baxter International (BAX) Now

Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.

Baxter's PrisMax Adopted by Hamilton Health Care System

AstraZeneca

Zoetis

They're flying high right now. But are these three healthcare stocks smart picks?

3 Healthcare Stocks at All-Time Highs: Are They Buys?

Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Baxter (BAX) Hits 52-Week High, Can the Run Continue?

First Horizon National

ICF International

OUTFRONT Media

5 Stocks -Trading Near 52-Week High With More Room to Run

Baxter is a leading medical device manufacturer. Its revenues are diverse and defensive.

Baxter: Defensive, Quality Holding With Upside Catalysts In Place

Edwards Lifesciences

Illumina

Intuitive Surgical

Johnson & Johnson

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Baxter (BAX) Moves to Buy: Rationale Behind the Upgrade

Baxter International, Inc. (BAX) CEO Joe Almeida on Q2 2019 Results - Earnings Call Transcript

The healthcare company delivered solid bottom-line improvement in Q2 on an operational and constant-currency basis.

Baxter Boosts Its Full-Year Outlook After Topping Q2 Estimates

Baxter earnings rose more than expected while sales also topped views. Shares of the medical technology firm rallied before the open, already in a buy range.

Baxter Earnings Growth Tops Views; Medtech Stock In Buy Zone

West Pharmaceutical Services

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

News for Baxter Stock (BAX)